These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23553755)

  • 21. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
    Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
    Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.
    De Felice F; Fiorilli R; Parma A; Menichelli M; Nazzaro MS; Pucci E; Dibra A; Musto C; Violini R
    Int J Cardiol; 2009 Mar; 132(3):337-41. PubMed ID: 18234373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
    Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
    EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stent thrombosis in randomized clinical trials of drug-eluting stents.
    Mauri L; Hsieh WH; Massaro JM; Ho KK; D'Agostino R; Cutlip DE
    N Engl J Med; 2007 Mar; 356(10):1020-9. PubMed ID: 17296821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the landscape of stent thrombosis: the drug-eluting versus bare-metal stent controversy.
    Rizik DG; Klassen KJ
    Am J Cardiol; 2008 Nov; 102(9 Suppl):4J-11J. PubMed ID: 18928786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Visualization of intimal proliferation of drug-eluting stent and bare mental stent by use of optical coherence tomography].
    Chen BX; Ma FY; Luo W; Xie WL; Sun SH; Guo XM; Wang F; Zhao XZ; Chu XW
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(16):1102-6. PubMed ID: 16796834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel polymer-free paclitaxel-eluting stent with a nanoporous surface for rapid endothelialization and inhibition of intimal hyperplasia: Comparison with a polymer-based sirolimus-eluting stent and bare metal stent in a porcine model.
    Jia H; Liu H; Kong J; Hou J; Wu J; Zhang M; Tian J; Liu H; Ma L; Hu S; Huang X; Zhang S; Zhang S; Yu B; Jang IK
    J Biomed Mater Res A; 2011 Sep; 98(4):629-37. PubMed ID: 21732525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
    Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug eluting stents based on Poly(ethylene carbonate): optimization of the stent coating process.
    Bege N; Steinmüller SO; Kalinowski M; Reul R; Klaus S; Petersen H; Curdy C; Janek J; Kissel T
    Eur J Pharm Biopharm; 2012 Apr; 80(3):562-70. PubMed ID: 22209978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study.
    Rittger H; Brachmann J; Sinha AM; Waliszewski M; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Breithardt OA; Schmidt M; Zimmermann S; Lonke S; von Cranach M; Nguyen TV; Daniel WG; Wöhrle J
    J Am Coll Cardiol; 2012 Apr; 59(15):1377-82. PubMed ID: 22386286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early and mid-term results of drug-eluting stent implantation in unprotected left main.
    Chieffo A; Stankovic G; Bonizzoni E; Tsagalou E; Iakovou I; Montorfano M; Airoldi F; Michev I; Sangiorgi MG; Carlino M; Vitrella G; Colombo A
    Circulation; 2005 Feb; 111(6):791-5. PubMed ID: 15699254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
    Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
    Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
    Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
    J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
    Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.